Methods of Application：
1.Simultaneous application using Connected Mixing System 2. Sequential Application
FIBINGLURAAS® consists of fibrinogen/FXIII and thrombin prepared from human plasma. Mixture of two components simulates the last phase of blood coagulation, activation of fibrinogen by thrombin and crosslinking of fibrin monomers to fibrin polymers leads to hemostasis before or after surgery and tissue glue.
Methods of Application：Subcutaneous injection. Prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent (sterile water for injection). After reconstitution, the final concentration of Tiluoting (thymalfasin) is 1.6 mg/ml.
Tiluoting’s effects on TLR9 lead to stimulation of the NFkappaB and p38 MAPK pathways, increased expression of the thymopoetic cytokines IFNα, IL-7, and IL-15, and stimulated macrophage activation and activity. Tiluoting stimulates the activity of indoleamine-2,3-dioxygenase (IDO) in plasmacytoid DCs, hence dampening immune response to prevent a pro-inflammatory cytokine storm and possibly autoimmune phenomena.